TVTX Travere Therapeutics Inc

Peter Heerma, an insider at Travere Therapeutics (NASDAQ:TVTX), sold 4,980 shares of the company's stock on December 24th, 2025, for a total of $199,200. This sale reduced his stake in the company by 4.22%, bringing his total ownership to 113,013 shares. The company recently reported strong financial results, beating analyst expectations for both revenue and EPS, and currently holds a "Moderate Buy" rating from analysts.

William E. Rote, Chief Research Officer at Travere Therapeutics (TVTX), sold 60,000 shares of common stock for approximately $2.4 million on December 24, 2025. This transaction was part of a prearranged 10b5-1 trading plan and followed the exercise of stock options. The sale occurred after a significant 124% stock price surge for TVTX over the past year, while the company prepares for potential profitability this year.

William Rote, an insider at Travere Therapeutics, sold 60,000 shares of TVTX stock on December 24th at an average price of $40.10, totaling $2,406,000. This transaction reduced his holding by over 37% to 101,443 shares. The company recently reported strong quarterly earnings, beating analyst estimates with $0.28 EPS and $164.86 million in revenue, leading to an average analyst rating of "Moderate Buy" with a target price of $38.71.

Traders recently purchased an unusually high volume of call options for Travere Therapeutics (NASDAQ:TVTX), indicating increased bullish sentiment despite insider selling. Analysts maintain a "Moderate Buy" rating with a consensus price target of $38.71, supported by recent price target upgrades. The company also reported a significant Q3 revenue beat, with revenue up 162% year-over-year.

Travere Therapeutics (NASDAQ: TVTX) is experiencing pre-market momentum as investors anticipate a January 13, 2026, FDA decision regarding FILSPARI (sparsentan) for focal segmental glomerulosclerosis (FSGS). The biotech stock recently rallied 14%, fueled by bullish analyst commentary and investor positioning ahead of this high-stakes regulatory event. The FDA's earlier decision not to hold an advisory committee meeting for FILSPARI in FSGS is seen by many as a de-risking signal, further intensifying investor focus on the upcoming PDUFA date.

Travere Therapeutics (TVTX) recently reached a 52-week high following favorable FDA regulatory adjustments for its drug FILSPARI, sparking a significant surge in its share price. While analysts have a consensus price target slightly below its current trading price, suggesting it's undervalued, investors are questioning if the market has fully priced in the upcoming January FSGS approval decision. The company's valuation, including an 8.3x price-to-sales ratio, is higher than its peer average, raising questions about whether this premium is currently justified.